2010 Fourth Quarter - released 03 February 2011
Andrew Witty, CEO, discusses our fourth quarter results 2010.
2010 Third Quarter - released 21 October 2010
Andrew Witty, CEO, discusses our third quarter results 2010
- Q3 EPS before major restructuring of 28.2p
- Q3 dividend up 7% to 16p
2010 Second Quarter - released 21 July 2010
Andrew Witty, CEO, discusses our second quarter results 2010.
- Q2 EPS before major restructuring 2.6p (29.3p excluding pre-announced legal charge)
- Q2 dividend increased 7% to 15p
2010 First Quarter - released 28 April 2010
Andrew Witty, CEO, discusses our first quarter results 2010.
- Q1 sales £7.4bn up 13% CER
- Underlying sales (excluding pandemic products) up 4% CER
Other key information
Speeches & presentations
Search through our archive of speeches and presentations from conferences and events
Keep up to date with our news and recent announcements
A snapshot of our medicines and vaccines currently in development across three stages: phase I, phase II and phase III
Corporate Executive Team
The Corporate Executive Team manages our activities, and each member is responsible for a specific part of the business